acarbose + insulin glargine + metformin

This is a combination therapy consisting of three antidiabetic agents—acarbose, insulin glargine, and metformin—used in the management of type 2 diabetes mellitus.\n- **Acarbose** is an oral alpha-glucosidase inhibitor that delays the digestion and absorption of carbohydrates in the intestine, thereby reducing postprandial blood glucose spikes.\n- **Insulin glargine** is a long-acting recombinant human insulin analog that provides basal insulin coverage for up to 24 hours by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.\n- **Metformin** is a biguanide oral antihyperglycemic agent that primarily decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity.\n\nThe combination targets multiple pathophysiological aspects of type 2 diabetes:\n- Acarbose reduces carbohydrate absorption after meals.\n- Insulin glargine maintains stable basal insulin levels.\n- Metformin lowers hepatic glucose output and increases tissue sensitivity to insulin.\n\nClinical studies have shown that combinations including these agents can improve glycemic control more effectively than monotherapy or dual therapy regimens[1][2][4]. This triple regimen may be considered for patients with inadequately controlled type 2 diabetes on fewer agents.